drugset / Trial / NCT02690857
Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)
RandomizedCrossoverQuadruple-blindTreatment
Summary
Patients with Cystic Fibrosis have increased oxidative stress and impaired antioxidant systems. Under certain conditions, docosahexaenoic acid (DHA) intake may have a favorable role in reducing redox status. In this randomized, double-blind, cross-over study, DHA (Pro-Mind) and placebo (sunflower oil) capsules, will be given, daily to 10 patients, 5 mg/kg for 2 weeks then 10 mg/kg for the next 2 weeks. Biomarkers of lipid peroxidation and vitamin E levels will be measured. Plasma and platelet lipid compositions will be determined.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DOCONEXENT | Other / unclassified | 10 mg/kg | Oral |